Xynomic Pharmaceuticals Holdings Inc股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，Immuron Ltd、Avrobio Inc、Scpharmaceuticals Inc涨幅较大，Immuron Ltd、Tonix Pharmaceuticals Holding Corp、Capricor Therapeutics Inc较为活跃，换手率分别为234.88%、75.67%、48.97%，振幅较大的相关个股有Immuron Ltd、Aevi Genomic Medicine Inc、Motif Bio Plc，振幅分别为77.13%、27.09%、26.57%。At 01:12 on July 17, 2019, Xynomic Pharmaceuticals Holdings Inc (XYN.us) shares fluctuated and fell sharply by 9.06%. As of press time, the stock was trading at US $2.91 per share, with a turnover of 6801 shares, a turnover rate of 0.01% and an amplitude of 6.25%.
The latest 2019-03-31 data show that the stock achieved operating income of $0.00, net profit of $32132.00, earnings per share of $0.01, gross profit of $0.00 and price-earnings ratio of-12.13 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the biotechnology industry in which Xynomic Pharmaceuticals Holdings Inc shares are located, the overall decline was 0.07 per cent. Among its related stocks, Immuron Ltd, Avrobio Inc and Scpharmaceuticals Inc rose significantly, while Immuron Ltd, Tonix Pharmaceuticals Holding Corp and Capricor Therapeutics Inc were more active, with turnover rates of 234.88%, 75.67% and 48.97% respectively. The related stocks with larger amplitudes were Immuron Ltd, Aevi Genomic Medicine Inc and Motif Bio Plc, with amplitudes of 77.13%, 27.09% and 26.57%, respectively.
About Xynomic Pharmaceuticals Holdings Inc: Xu Nuo Pharmaceutical Co., Ltd. is an American company headquartered in Shanghai. XuNuo Pharmaceutical Co., Ltd. focuses on authorizing the introduction, development and commercial sale of new antineoplastic drugs worldwide. The company has a strong product pipeline, including Abexinostat (global equity) and BI 882370 (global equity), and will introduce other oncology products in the near future. Abexinostat is an innovative histone deacetylase inhibitor for the treatment of hematological and solid tumors with the best potential of its kind. The drug has completed 17 phase 1 and phase 2 clinical trials in the United States, the European Union and Asia, showing that it has clinical efficacy in a variety of tumors and has better overall safety in similar histone deacetylase inhibitors. XuNuo Pharmaceutical launched a phase 3 notifiable clinical trial worldwide in the third quarter of 2017. BI 882370 is a very potent, highly selective, inactive conformational (DFG-out) Raf inhibitor. The company's founding team has worked in multinational biopharmaceutical companies (Schering,Eli Lilly and Co, Merck,Roche、Bristol-Myers Squibb CoEngaged in R & D, clinical and business work. Mr. Xu Yinglin, co-founder, chairman, CEO and president of the company, is a successful serial entrepreneur who has co-founded two US-China biopharmaceutical companies and achieved a successful exit of RMB 2.5 billion for the company's shareholders.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )
